SMARCA1 and cancer: However, due to the fact that the SWI/SNF subunit mutations are observed in a wide range of malignant neoplasms [103,104,105] and that there are drugs that target these genetic alterations, the same targeted therapies could possibly enhance anti-cancer treatment effectiveness and provide new insights for therapeutic strategies in EDC.